Author

Tamás Ferenci 1

1 Óbuda University,Budapest,Hungary

ADVANCES IN OPTIMALIZATION OF THERAPEUTIC DRUG MONITORING USING MUCOSAL TNF EXPRESSION AND ANTI-TNF CONCENTRATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH BIOLOGICALS - PRELIMINARY RESULTS FROM A SINGLE CENTER STUDY

Klaudia Farkas, Gréta Elekes, Diána Kata, Imre Földesi, Tamás Ferenci, Tamara Madacsy, Mariann Rutka, Anita Balint, Renáta Bor, Anna Fabian, Ágnes Milassin, Szilvia Lada, Zoltan Gabor Szepes, Ferenc Nagy, József Maléth, Tamás Molnár

BODY COMPOSITION AS A PREDICTOR FACTOR OF DISEASE OUTCOME IN INFLAMMATORY BOWEL DISEASE – RESULTS OF 3-YEAR FOLLOW UP

Agnes Anna Csontos, Andrea Molnár, Rita Hencz, Dóra Piri, Sarolta Dakó, Tamás Ferenci, Erzsébet Pálfi, Pal Miheller

INFLIXIMAB BIOSIMILAR CT-P13 THERAPY IS EFFECTIVE IN MAINTAINING CLINICAL AND ENDOSCOPIC REMISSION IN CROHN?S DISEASE AND ULCERATIVE COLITIS ? EXPERIENCES FROM A SINGLE CENTER

Klaudia Farkas, Mariann Rutka, Tamás Ferenci, Ferenc Nagy, Anita Balint, Renáta Bor, Ágnes Milassin, Anna Fabian, Zoltan Gabor Szepes, Tamás Molnár

RELATIONSHIP BETWEEN SERUM INFLIXIMAB TROUGH LEVELS AND LABORATORY PARAMETERS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Anna Fabian, Klaudia Farkas, Dema Kanaaneh, Anita Balint, Renáta Bor, Mariann Rutka, Ágnes Milassin, Tamás Ferenci, Ferenc Nagy, Zoltan Gabor Szepes, Tamás Molnár

Item 1 - 4 / 4
1